These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 19573049)

  • 1. Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring.
    Sparshatt A; Taylor D; Patel MX; Kapur S
    Acta Psychiatr Scand; 2009 Dec; 120(6):416-28. PubMed ID: 19573049
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic drug monitoring for optimizing amisulpride therapy in patients with schizophrenia.
    Müller MJ; Regenbogen B; Härtter S; Eich FX; Hiemke C
    J Psychiatr Res; 2007 Oct; 41(8):673-9. PubMed ID: 16324716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder.
    Müller MJ; Eich FX; Regenbogen B; Sachse J; Härtter S; Hiemke C
    J Psychopharmacol; 2009 May; 23(3):278-86. PubMed ID: 18562411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma amisulpride levels in schizophrenia or schizoaffective disorder.
    Bergemann N; Kopitz J; Kress KR; Frick A
    Eur Neuropsychopharmacol; 2004 May; 14(3):245-50. PubMed ID: 15056484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. D2 receptor occupancy during high- and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study.
    la Fougère C; Meisenzahl E; Schmitt G; Stauss J; Frodl T; Tatsch K; Hahn K; Möller HJ; Dresel S
    J Nucl Med; 2005 Jun; 46(6):1028-33. PubMed ID: 15937316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prolactinemia is uncoupled from central D2/D3 dopamine receptor occupancy in amisulpride treated patients.
    Bressan RA; Erlandsson K; Spencer EP; Ell PJ; Pilowsky LS
    Psychopharmacology (Berl); 2004 Sep; 175(3):367-73. PubMed ID: 14997280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender aspects in the clinical treatment of schizophrenic inpatients with amisulpride: a therapeutic drug monitoring study.
    Müller MJ; Regenbogen B; Sachse J; Eich FX; Härtter S; Hiemke C
    Pharmacopsychiatry; 2006 Mar; 39(2):41-6. PubMed ID: 16555163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study.
    Meisenzahl EM; Schmitt G; Gründer G; Dresel S; Frodl T; la Fougère C; Scheuerecker J; Schwarz M; Boerner R; Stauss J; Hahn K; Möller HJ
    Pharmacopsychiatry; 2008 Sep; 41(5):169-75. PubMed ID: 18763218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is amisulpride an 'atypical' atypical antipsychotic agent?
    Lecrubier Y
    Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S21-6. PubMed ID: 11252520
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease.
    Reeves S; McLachlan E; Bertrand J; D'Antonio F; Brownings S; Nair A; Greaves S; Smith A; Taylor D; Dunn J; Marsden P; Kessler R; Howard R
    Brain; 2017 Apr; 140(4):1117-1127. PubMed ID: 28334978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of dopamine research in schizophrenia.
    Pani L
    Curr Med Res Opin; 2002; 18 Suppl 3():s3-7. PubMed ID: 12418605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Population Approach to Guide Amisulpride Dose Adjustments in Older Patients With Alzheimer's Disease.
    Reeves S; Bertrand J; McLachlan E; D'Antonio F; Brownings S; Nair A; Greaves S; Smith A; Dunn JT; Marsden P; Kessler R; Uchida H; Taylor D; Howard R
    J Clin Psychiatry; 2017 Jul; 78(7):e844-e851. PubMed ID: 28858444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
    Mamo D; Graff A; Mizrahi R; Shammi CM; Romeyer F; Kapur S
    Am J Psychiatry; 2007 Sep; 164(9):1411-7. PubMed ID: 17728427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic D2/3 receptor occupancies and response with low amisulpride blood concentrations in very late-onset schizophrenia-like psychosis (VLOSLP).
    Reeves S; Eggleston K; Cort E; McLachlan E; Brownings S; Nair A; Greaves S; Smith A; Dunn J; Marsden P; Kessler R; Taylor D; Bertrand J; Howard R
    Int J Geriatr Psychiatry; 2018 Feb; 33(2):396-404. PubMed ID: 28643852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic review of aripiprazole--dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring.
    Sparshatt A; Taylor D; Patel MX; Kapur S
    J Clin Psychiatry; 2010 Nov; 71(11):1447-56. PubMed ID: 20584524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The features of atypical neuroleptic amisulpride action].
    Grigor'eva EA; Ritskov AS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2004; 104(6):59-64. PubMed ID: 15285638
    [No Abstract]   [Full Text] [Related]  

  • 17. Dopaminergic deficit and the role of amisulpride in the treatment of schizophrenia.
    Kasper S
    Int Clin Psychopharmacol; 2002 Dec; 17 Suppl 4():S19-26. PubMed ID: 12685918
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Amisulpride, neuroleptic and antinegative action].
    Widlöcher D; Allilaire JF; Guérard des Lauriers A; Lecrubier Y
    Encephale; 1990; 16(2):159-63. PubMed ID: 1972055
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
    Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
    Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of amisulpride (Solian): a review of 11 clinical studies.
    Coulouvrat C; Dondey-Nouvel L
    Int Clin Psychopharmacol; 1999 Jul; 14(4):209-18. PubMed ID: 10468313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.